Endexx Announces Patient Enrollment in Clinical Study of Proprietary CBD Capsule Formulation for Treatment of …

CAVE CREEK, AZ–(Marketwired – Jun 22, 2016) – Endexx Corporation (OTC PINK: EDXC), a provider of innovative hemp derived phyto-nutrients and nutritional health products, announced today that approximately 40 patients have enrolled in an adaptive clinical study to test the efficacy of its proprietary CBD capsule in alleviating symptoms for patients suffering from neuropathic pain.

The clinical trial, conducted at four sites by four physicians, is an extension of the work conducted by Dr. Daniel Kiddy and a follow up of Dr. Daniel Brandwein who will enroll up to eighty 80 patients into four groups of twenty, for a one-month study using CBD enriched capsules to evaluate neuropathic pain reduction. The proprietary formulations are manufactured in a regulated compound pharmacy and designed by the doctor and pharmacist. The formulated and manufactured capsules utilized in this study include a dual pack as a day and night formula with cannabidiol as its

... read more at: http://www.marketwired.com/press-release/endexx-announces-patient-enrollment-clinical-study-proprietary-cbd-capsule-formulation-otc-pink-edxc-2136509.htm